secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0000885725-23-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q2 beats: $3.599B revenue (+11% reported), adj. EPS $0.53 vs guidance $0.48-$0.50
--------------------------------------------------------------------------------

- Revenue $3.599B, +11% reported, +11.6% organic; beat guidance of 6.5-8.5% reported.
- GAAP EPS $0.18 (GAAP net income $261M); adjusted EPS $0.53 vs guidance $0.48-$0.50.
- Cardiovascular segment grew 12.2% reported; MedSurg grew 9.0% reported.
- Full-year 2023 guidance raised: reported revenue growth ~10.5-11.5%, adj. EPS $1.96-$2.00.
- Q3 guidance: reported revenue growth 8.5-10.5%, adj. EPS $0.46-$0.48.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572523000041/0000885725-23-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572523000041/bsx-20230727.htm
  HTML page:      https://secwatch.observer/filing/0000885725-23-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer